Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
J. Clin. Oncol 2023 Jul 28;[EPub Ahead of Print], PA Ascierto, R Dummer, HJ Gogas, A Arance, M Mandala, G Liszkay, C Garbe, D Schadendorf, I Krajsova, R Gutzmer, V Chiarion-Sileni, C Dutriaux, JWB de Groot, N Yamazaki, C Loquai, C Robert, KT FlahertyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.